Nike founder Phil Knight has offered over US$2 billion to Paul Allen Trust for the purchase of the Portland Trail Blazers basketball team, according to a report by ESPN.
The Portland-born billionaire stepped down as chairman and chief executive of Nike in 2016.
The Paul Allen Trust is part of an investment group that also includes Los Angeles Dodgers part-owner Alan Smolinisky.
According to ESPN, Knight and Smolinisky have discussed a prospective takeover with the NBA league office.
The Trail Blazers acknowledged the Knight group's written offer, but reiterated that "the team remains not for sale."
Last year, Forbes valued the Blazers at $2.05 billion.
Since the franchise's previous owner died in October 2018, the Paul Allen Trust has been in charge of it. Allen's sister, Jody, took over the trust and its affairs.
Knight, like Silver, is said to want to keep the Blazers in Portland, a city with which he has strong ties.
Last week, NBA commissioner Adam Silver stated that the Blazers will have to be sold "at some point," but that no timetable for such a sale has been set.


Trump’s U.S. Open Visit Delays Final, Fans Face Long Security Lines
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows
Republican Lawmakers Urge National Guard Role for World Cup Drone Security
Native American Groups Slam Trump’s Call to Restore Redskins Name
OpenAI Rules Out 2026 IPO as Altman Prioritizes AI Safety
FBI Faces Historic Security Challenge Ahead of 2026 FIFA World Cup
FIFA Faces Investigation Over 2026 World Cup Ticket Pricing and Seat Allocation Issues
JD Vance to Lead U.S. Presidential Delegation at Milano Cortina Winter Olympics Opening Ceremony
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
SpaceX Nasdaq 100 Weight Set to More Than Double
ECB Rate Hike in Focus as Oil Tops $100
Fitch Eyes Japan Budget for Fiscal Discipline
TSMC August Revenue Jumps 53% on AI Chip Demand
US Reviewing Visa Denial for Venezuelan Little League Team Barred from World Series
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 



